At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Tenalisib,drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Phase II Study to Evaluate the Efficacy and Safety of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Adult Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)
In Brief
A Phase 2 clinical trial evaluating Tenalisib, for Non Hodgkin Lymphoma. Completed, enrolled 20 participants across 12 sites in 2 countries.
Detailed Summary
To assess the anti-tumor activity and safety of Tenalisib in patients with relapsed/refractory indolent Non-Hodgkin's Lymphoma (iNHL),
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Hodgkin Lymphoma
CountriesAustralia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartNov 2018
Primary CompletionJun 2020
Study CompletionOct 2020
TodayJul 2026
First PostedOct 18, 2018
Enrollment StartNov 25, 2018
Primary CompletionJun 16, 2020
Study CompletionOct 16, 2020
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 7.7 years ago
Interventions
Tenalisib,drug
BID, Orally